16 September 2026 editorial review · Item
Dexcom G7 15-Day: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Dexcom G7 15-Day
Scope and findings:
- Verified affected iOS versions and software correction mechanism against live Medsafe database (updated September 11). Added omitted ONE+ correction; G7 notices retained. Not a fresh independent accuracy comparison or exhaustive global recall search.
- Read FDA decision summary: 15-day system indicated for adults 18+, with compatible connected-device limitations. Full-wear survival and MARD remain population-level study estimates, not guaranteed individual duration.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.